VistaGen Therapeutics News

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management

BusinesswireMay 7 20:30

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)

TipRanksApr 27 20:10

Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.

BusinesswireApr 25 20:30

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

BusinesswireApr 9 20:30

30 Countries With the Lowest Depression Rates

Yahoo FinanceMar 26 18:24

This Overlooked Corner of Women's Health Could Be a $350 Billion Market Opportunity

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

CNBCMar 16 02:33

Vistagen to Present at Stifel 2024 Virtual CNS Days

Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management

BusinesswireMar 11 20:30

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management

BusinesswireFeb 28 21:30

10 Health Care Stocks Whale Activity In Today's Session

Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.

BenzingaFeb 20 01:35

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript

Yahoo FinanceFeb 15 21:20

Earnings Call: Vistagen Reports on Clinical Updates and Financial Health

InvestingFeb 15 10:02

Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q3 2024 Earnings Conference

The following is a summary of the Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript:Financial Performance:VistaGen reported a net loss of $6.3 million in Q3 2024, improving from the

Futu NewsFeb 14 07:50 · Conference Call

Vistagen Therapeutics Files for $350M Mixed Shelf

Seeking AlphaFeb 14 06:04

VistaGen Therapeutics GAAP EPS of -$0.22 Beats by $0.08, Revenue of $0.41M Misses by $0.13M

Seeking AlphaFeb 14 05:33

Recap: Vistagen Therapeutics Q3 Earnings

Vistagen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Tuesday, February 13, 2024 at 04:21 PM.Here's what investors need to know about the announcement.EarningsVistagen Therapeutics b

BenzingaFeb 14 05:25

Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400

04:21 PM EST, 02/13/2024 (MT Newswires) -- Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400

MT NewswiresFeb 14 05:21

VistaGen Therapeutics 3Q Loss/Shr 22c >VTGN

VistaGen Therapeutics 3Q Loss/Shr 22c >VTGN

Dow JonesFeb 14 05:20

Earnings Scheduled For February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. • Navios Maritime Partners (NYSE:NMM) is projected

BenzingaFeb 13 18:05

VistaGen Therapeutics's Earnings: A Preview

VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here's what investors need to know before the announcement.Analysts estimate that VistaG

BenzingaFeb 13 03:01

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference

BusinesswireFeb 6 21:30